ProCE Banner Activity

IKEMA Subgroup Analyses: Isatuximab Plus Carfilzomib/Dex vs Carfilzomib/Dex in Patients With Relapsed/Refractory MM

Slideset Download
Conference Coverage
Addition of isatuximab to carfilzomib/dexamethasone improved PFS in patients with difficult-to-treat R/R MM, including older patients, patients with MM refractory to previous therapy, and those with high-risk cytogenetics.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme